Canada: Canada’s Utility Requirement For Patentability – Looking For Good News For The Innovative Pharmaceutical Industry

Last Updated: November 14 2013
Article by Patricia Folkins and Andrea Berenbaum


To be patentable in Canada, an invention must not only be new and non-obvious, it must also have utility.1 As evidenced by Eli Lilly's recent filing of a Notice of Arbitration in a $500 million NAFTA2 dispute against Canada for the invalidation of two of its patents covering its key drug products, Strattera and Zyprexa, on the basis of lack of utility3, it is clear that the issue of utility is currently a controversial subject at the forefront of the Canadian patent law.

The utility requirement may be met by either demonstrating that the invention possesses the claimed utility or by relying on sound prediction. In either case, it has been established that the relevant date for determining utility is the Canadian filing date.4 Accordingly, post-filing evidence and/or knowledge is not presently of assistance for establishing utility.

Two sub-issues emerge upon review of the case law from the past 10 years related to utility of a claimed invention. These two sub-issues are (1) the doctrine of the promise of the patent and (2) the doctrine of sound prediction. One of the bases for Eli Lilly's claims in its NAFTA challenge against Canada, is that the courts have established a "heightened disclosure requirement" for utility and, in their reasons, Lilly refers to these two doctrines.

Often cited as the case for the basis of the doctrine of the promise of the patent is the Supreme Court of Canada (SCC) decision in Consolboard Inc v MacMillan Bloedel5, "Consolboard", in which it stated on page 525:

There is a helpful discussion in Halsbury's Laws of England, (3rd ed.), vol. 29, at p. 59, on the meaning of "not useful" in patent law. It means "that the invention will not work, either in the sense that it will not operate at all or, more broadly, that it will not do what the specification promises that it will do".

A more recent citation, Eli Lilly Canada Inc v Novopharm Limited6, "Olanzapine", is also frequently referred to when addressing the promise of a patent in a utility analysis. In that decision, the following passage at paragraph 76 is often quoted:

Where the specification does not promise a specific result, no particular level of utility is required; a "mere scintilla" of utility will suffice. However, where the specification sets out an explicit "promise", utility will be measured against that promise: Consolboard; Pfizer Canada Inc. v. Canada (Minister of Health), [2009] 1 F.C.R. 253, 2008 FCA 108 (Ranbaxy). The question is whether the invention does what the patent promises it will do.

The seminal case for citations related to the doctrine of sound prediction is Apotex Inc v Wellcome Foundation Ltd7, "AZT", in which the SCC confirmed that utility may be based upon a sound prediction so long as there is a factual basis for the prediction, the inventor has an articulable and sound line of reasoning from which the desired result can be inferred from the factual basis, and there is proper disclosure. However, as it was not at issue in the case, the SCC did not set out what is necessary to satisfy the requirement of "proper disclosure". Subsequent decisions of the Canadian Federal Court of Appeal (FCA) appeared to hold that the factual basis8 and the sound line of reasoning9 must be found in the patent itself.

While many reports tend to focus on the bad news, this article attempts to highlight some recent cases where helpful clarifying statements have been presented that may help patentees defend their inventions with the Canadian Patent Office as well as in Canada's Courts.

Recent Cases

The recent decision of the FCA in Sanofi-Aventis v Apotex Inc10, "Plavix II", provides some good news on both the promise of the patent and the sound prediction fronts. As we previously reported11, the Federal Court12 initially found Sanofi's Canadian Patent No. 1,336,777 (the '777 Patent) invalid, holding that the utility of the invention had neither been demonstrated nor soundly predicted as of the filing date of the patent application.

On appeal, the FCA concluded that the Federal Court erred in reading into the '777 Patent a promise for use in humans on the basis of inferences and ultimately found that the '777 Patent was valid13. Particularly helpful are the following comments at paragraph 50 by Justice Pelletier:

... it should not be taken to have assumed that every patent contains an explicit promise of a specific result since, subject to what is said below with respect to selection patents14, there is no obligation on the part of the inventor to disclose the utility of his invention in the patent.

Further, Plavix II referred to earlier decisions15 that emphasized that, by simply alluding to the possibility of a result, for example, by reference to specific advantages or goals, does not necessarily mean that "the inventors were ... promising that this result had been or would be achieved"16.

In a very recent decision from the Federal Court17, Justice Hughes reiterated this opinion:

The list of "advantages", commencing at page 9 and over to page 10, has previously been set out in these Reasons. That list should not be elevated to a "promise"; it is simply an observation as to advantages expected to be achieved. ...18

While the major issue with respect to the utility analysis in Plavix II related to the controversial "promise of the patent" doctrine, the concurring reasons of Justice Gauthier are also noteworthy for their comments on sound prediction disclosure requirements, suggesting that these requirements may differ depending on the subject-matter claimed in the patent. For example, at paragraphs 134-135 of the decision, Justice Gauthier states:

In contradistinction with the situation in AZT, where the invention claimed was the new use/utility and thus the quid pro quo for the grant of the monopoly was a full disclosure in respect of such utility, the public here received all the information necessary to make and use clopidogrel, the invention claimed in the '777 Patent. ...

In such a case, the level of disclosure required by law should be lower. ...

In other words, Justice Gauthier seems to suggest here that the level of disclosure required to support the utility of a new compound should be less than that to support a new use. As noted by Justice Gauthier, this is in line with the seminal sound prediction case, AZT, where Justice Binnie stated at paragraph 56:

Where the new use is the gravamen of the invention, the utility required for patentability (s. 2) must, as of the priority date, either be demonstrated or be a sound prediction based on the information and expertise then available. ...

Another recent decision of the FCA also suggested that a more contextual approach to determining what is necessary to satisfy the requirement of "proper disclosure" is being developed. In Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée19, "Eurocopter" it was held that:

... where the sound prediction is based on knowledge forming part of the common general knowledge and on a line of reasoning which would be apparent to the skilled person (which is often the case in mechanical inventions), the requirements of disclosure may readily be met by simply describing the invention in sufficient detail such that it can be practiced. A contextual approach is thus appropriate in each case.20

Regarding this contextual approach, the decision of the FCA in Eurocopter went further and suggested that the requirements for sound prediction in a particular case will be dependent on the determination of who the skilled person is and what is their common general knowledge:

... the factual basis, the line of reasoning and the level of disclosure required by the doctrine of sound prediction are to be assessed as a function of the knowledge that the skilled person would have to base that prediction on, and as a function of what that skilled person would understand as a logical line of reasoning leading to the utility of the invention.21

Going even further, the FCA in Eurocopter provided that, if the factual basis can be found in the common general knowledge of a person skilled in the art, it also does not necessarily need to be disclosed in the patent:

Where the factual basis can be found in scientifically accepted laws or principles or in information forming part of the common general knowledge of the skilled person, then no disclosure of such factual basis may be required in the specification.22

The Federal Court in Teva Canada Limited v Novartis AG23, "Imatinib" also stated that the common general knowledge of a person skilled in the art can be used to bridge a "gap" in the disclosure between a factual basis provided in the patent and the prediction of the inventor, so long as the patent provides more disclosure than the prior art.

The holdings in Imatinib and Eurocopter are generally in line with the stated position of the Canadian Patent Office, which, in its Manual of Patent Office Practice24, "MOPOP" suggests that elements of the factual basis and/or the sound line of reasoning forming part of the common general knowledge of a skilled person do not need to be explicitly disclosed in an application.25

While the majority of the claims at issue in Eurocopter ultimately failed to meet the sound prediction disclosure requirements, this case, along with Imatinib, provide validity to the argument that the disclosure requirement for sound prediction can be met by relying on the knowledge of a person skilled in the art, when the technology allows.


The statements found in the cases referred to above regarding disclosure requirements for sound prediction as well the impropriety of improperly using the Applicant's own disclosure to make inferences that result in a heightened level for the promise of the patent, provide some hope and good news for innovative pharmaceutical patentees in Canada. This is most welcome in a time which has seen a considerable amount of bad news when it comes to upholding the validity of pharmaceutical patents in court challenges and we hope signals a move to a more moderate approach.


1 Patent Act, RSC 1985, c P-4, s 2.

2 North American Free Trade Agreement Between the Government of Canada, the Government of Mexico and the Government of the United States, 17 December 1992, Can TS 1994 No 2, 32 ILM 289 (entered into force 1 January 1994) [NAFTA].

3 See our report at:

4 Aventis Pharma Inc v Apotex Inc, 2006 FCA 64, para 30.

5 Consolboard Inc v MacMillan Bloedel (Sask) Ltd, [1981] 1 SCR 504.

6 Eli Lilly Canada Inc v Novopharm Limited, 2010 FCA 197.

7 Apotex Inc v Wellcome Foundation Ltd, 2002 SCC 77, [2002] 4 SCR 153.

8 Eli Lilly Canada Inc v Apotex Inc, 2009 FCA 97.

9 Apotex Inc v Pfizer Canada Inc, 2011 FCA 236.

10 Sanofi-Aventis v Apotex Inc, 2013 FCA 186.


12 Apotex Inc v Sanofi-Aventis, 2011 FC 1486.

13 Reported in greater detail in:

14 Plavix II confirmed that selection patents must set out an explicit promise because both "the novelty of the selection and its advantages (including disadvantages to be avoided) are the invention and must be described in the patent". Plavix II at para 51.

15 For example: AstraZeneca Canada Inc v Mylan Pharmaceuticals ULC, 2011 FC 1023 at para 139; Pfizer Canada Inc v Mylan Pharmaceuticals ULC, 2012 FCA 103 at para 61; and Mylan Pharmaceuticals ULC v Canada (Minister of Health) , 2012 FCA 109 at paras 32-33.

16 Plavix II at para 67.

17 Bayer Inc v Cobalt Pharmaceuticals Company, 2013 FC 1061.

18 Ibid at para 152.

19 Bell Helicopter Textron Canada Limitée v Eurocopter, société par actions simplifiée, 2013 FCA 219. This decision is also of interest for its holding that the doctrine of sound prediction can apply to the field of mechanical inventions and is not limited to pharmaceutical inventions (See Eurocopter, para 146).

20 Ibid at para 155.

21 Ibid at para 152.

22 Ibid at para 153.

23 Teva Canada Limited v Novartis AG, 2013 FC 141.

24 Canadian Intellectual Property Office, "Manual of Patent Office Practice" (December 2010), online:

25 See, for example: MOPOP, § 12.08.04.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Patricia Folkins
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.